GlassScriptPhysician profile
Danielle Wilson
NPI 1770061301
$3,553.89
in general payments reported to CMS, 2019-2025
38 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.08 · 2022: $846 · 2023: $978 · 2024: $982 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.34 | 2022-2025 | |
| Lilly USA, LLC | $259.87 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $247.19 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $227.89 | 2022-2025 | Trintellix |
| Exact Sciences Corporation | $220.30 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.72 | 2021-2025 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $154.97 | 2022-2024 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $154.88 | 2023-2025 | Auvelity |
| Lundbeck LLC | $137.39 | 2022-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $122.39 | 2023-2025 | Rexulti |
| Amgen INC. | $120.19 | 2022-2024 | Otezla, Repatha |
| Almatica Pharma LLC | $113.42 | 2022-2025 | Gralise, Loreev Xr |
| Shield Therapeutics INC | $83.73 | 2022-2025 | |
| Pfizer INC. | $66.82 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.49 | 2022-2024 | Caplyta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $56.85 | 2024-2025 | Impella |
| Aveo Pharmaceuticals, INC. | $48.56 | 2023-2024 | Fotivda |
| Alkermes, INC. | $47.78 | 2022-2023 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $44.99 | 2022-2024 | Dificid, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $44.46 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.32 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.12 | 2023-2025 | Xifaxan |
| Pharmacyclics LLC, An Abbvie Company | $35.65 | 2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $34.70 | 2022-2025 | |
| Corium, LLC | $34.47 | 2025 | Azstarys |
| Tris Pharma INC | $31.21 | 2022-2025 | Dyanavel Xr |
| Astellas Pharma US INC | $24.95 | 2023 | Veozah |
| Alk-Abello, INC | $24.90 | 2025 | Odactra, Ragwitek, Grastek |
| Azurity Pharmaceuticals, INC. | $24.82 | 2025 | Danziten |
| Phathom Pharmaceuticals, INC. | $22.32 | 2024 | Voquezna |
| Abbott Laboratories | $21.67 | 2025 | Assurity |
| Xeris Pharmaceuticals, INC. | $21.66 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $21.20 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $21.18 | 2023 | |
| Evoke Pharma, INC. | $17.83 | 2024 | |
| Cranial Technologies, INC | $16.38 | 2023 | Doc Band |
| Amarin Pharma, INC. | $14.49 | 2021 | |
| Sage Therapeutics, LLC | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.